|Articles|October 2, 2015

Emerging Life-Sciences Markets: New Partnerships, New Competitors

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies. JLL’s 2015 Life Sciences Outlook report highlights global clusters worth watching.

BioPharm International

eBooks Volume 28, Issue 14

Distant destinations have never looked better for multinational and middle market life-sciences companies. While multinationals fill their innovation pipelines in North America, branded and generic-drug producers alike are finding fertile ground for growth in new markets in Asia and Latin America. Read this article and other articles in

BioPharm International

's 2015

The Future of Bioprocessing

eBook.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

3D illustration of blue Y-shaped antibodies with glowing yellow-green capsules attached to their arms, floating near the textured surface of a large green cell against a blurred blue background. | Image Credit: © ustas - stock.adobe.com

October 19th, 2026

Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets

Roche will take ex-China development of Hansoh’s two preclinical ADCs and multiple programs against Roche-proposed targets once Hansoh completes global phase 1a trials. The deal includes $400 million upfront and more than $15 billion in potential milestones.

Two researchers in lab coats, safety glasses, and blue gloves review data on a computer monitor in a laboratory, with racks of sample tubes and a microscope on the bench and a third researcher working in the background. | Image Credit: © DC Studio - stock.adobe.com

October 16th, 2026

FAQ: When Big Pharma Drops a Drug Candidate, Who Picks It Up?

When large pharmaceutical companies deprioritize drug candidates, smaller developers may license or acquire them, but due diligence, deal structure, and trial planning determine whether a program can move forward.

Technologist in white protective uniform controlling industrial process using tablet computer. | Image credit: © littlewolf1989 - © littlewolf1989 - stock.adobe.com

October 22nd, 2026

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.

3d rendered medically accurate illustration of the gallbladder cancer | Image credit: © Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com

October 21st, 2026

Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US

EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC.

3D illustration of three gold spherical nanoparticles on a black background, one shown in cross-section with a layer of lipid molecules around a glowing core, and a blue single-stranded nucleic acid winding around it. | Image Credit: © Love Employee - stock.adobe.com

October 20th, 2026

METiS TechBio, Lilly Partner on AI-Designed LNPs for Tissue-Specific Delivery

METiS TechBio will apply its AI-driven AiLNP ionizable lipid platform to discover LNPs designed to deliver therapeutics beyond the liver, under a collaboration with Eli Lilly worth up to $1.1 billion in milestones.

A person in a light blue blazer holding their abdomen with both hands, with an illustration of the intestines overlaid on the torso and a red glow highlighting the small intestine. | Image Credit: © eddows - stock.adobe.com

October 20th, 2026

Bionyra’s Long-Acting Anti-TL1A Antibody BYN-002 Shows Roughly 80-Day Half-Life in Phase 1

Interim phase 1 data presented at UEG Week 2026 showed Bionyra Pharma’s Fc-engineered anti-TL1A antibody BYN-002 suppressed soluble TL1A with a half-life supporting potential every-3-to-6-month maintenance dosing in IBD.

A child in a light pink tie-dye shirt holds a pink paper cutout of the large and small intestines in front of their abdomen. | Image Credit: © SewCreamStudio - stock.adobe.com

October 19th, 2026

Lilly’s Omvoh Reaches 50% One-Year Remission in Pediatric Ulcerative Colitis

In the phase 3 SHINE-2 trial, half of pediatric patients who responded to mirikizumab induction were in clinical remission at week 52. Lilly plans to file for a pediatric UC label expansion.

Research and scanning eye, close-up photos, retinal diagnostics in ophthalmology | Image credit: © Анна Ковальчук - © �Анна Ковальчук - stock.adobe.com

October 15th, 2026

Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid

AVT29, a proposed aflibercept biosimilar to Eylea 8 mg, could extend retinal disease treatment intervals to 16 weeks, versus 8 weeks today.

Emerging Life-Sciences Markets: New Partnerships, New Competitors

Related to this article

Trending on BioPharm International

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy

TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens